Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 1

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
     203,103  
     195,754 
  
    Accumulated other comprehensive loss 
     (610) 
     (575)
  
    Accumulated deficit 
     (172,843) 
     (163,104)
  
    TOTAL STOCKHOLDERS’ EQUITY 
     29,673  
     32,097 

    TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY 
    $37,801  
    $39,562 

The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.

1

INMUNE BIO INC. 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

    For the Three Months Ended  March 31, 

    2025  
    2024 
  
    REVENUE 
    $50  
    $14 

    OPERATING EXPENSES 

    General and administrative 
     2,316  
     2,338 
  
    Research and development 
     7,639  
     8,693 
  
    Total operating expenses 
     9,955  
     11,031 

    LOSS FROM OPERATIONS 
     (9,905) 
     (11,017)

    OTHER INCOME (EXPENSE), NET 
     166  
     (8)

    NET LOSS 
    $(9,739) 
    $(11,025)

    Net loss per common share – basic and diluted 
    $(0.43) 
    $(0.61)

    Weighted average common shares outstanding – basic and diluted 
     22,496,191  
     18,026,473 

    COMPREHENSIVE LOSS 

    Net loss 
    $(9,739) 
    $(11,025)
  
    Other comprehensive income (loss) – foreign currency translation 
     (35) 
     130 
  
    Total comprehensive loss 
    $(9,774) 
    $(10,895)

The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.

2

INMUNE BIO INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES
IN STOCKHOLDERS’ EQUITY

FOR THE THREE MONTHS ENDED MARCH